# A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

> **NCT01659047** · PHASE2 · WITHDRAWN · sponsor: **Gilead Sciences**

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** GS-1101

## Key facts

- **NCT ID:** NCT01659047
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-08
- **Primary completion:** 2014-12
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01659047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01659047, "A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01659047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*